Elite Pharmaceuticals replaces auditor: Mazars USA succeeded by Forvis Mazars, LLP after Mazars USA merger

ELITE PHARMACEUTICALS INC /NV/

Mazars USA resigned as auditor effective June 1, 2024, as substantially all partners/employees joined Forvis, LLP (renamed Forvis Mazars, LLP).
Forvis Mazars appointed as new independent registered public accounting firm, effective same date, approved by Audit Committee and Board.
No disagreements or reportable events between company and Mazars USA during past two fiscal years and interim period.
No prior consultations with Forvis Mazars regarding accounting principles or audit opinions before appointment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.